Abstract
Objective
In patients with differentiated thyroid cancer (DTC), recurrences may occur in up to 20% and may have a fatal outcome in 10% of cases. Thyroglobulin doubling time (Tg-DT) values may contribute to predict response to treatment and disease recurrence in DTC patients. This study aimed to address the following questions: (1) Are Tg-DT values indicative of response to treatments in patients with DTC (i.e. ’treatment monitoring’)?; (2) Is Tg-DT predictive of 2-[18F]fluoro-2-deoxy-d-glucose (2-[18F]FDG) PET/CT in patients with DTC?; (3) Are Tg-DT values predictive of DTC prognosis (i.e. ‘prediction’)?
Design
Systematic review and meta-analysis.
Methods
Methodology was registered in the PROSPERO database (CRD42021257947). A systematic search was carried out in PubMed, Web Of Science, and Scopus from June to August 2021 without time and language restrictions.
Results
Eleven studies were included for a total of 1421 patients. Positive association between Tg-DT < 1 year and recurrence or disease progression was observed. Tg-DT was found to be related with (2-[18F]FDG) PET/CT results in patients with DTC. The area under the curve was 0.86 (95% CI: 0.83–0.89), sensitivity was 0.84 (0.64;0.94), specificity was 0.71 (0.35; 0.92), DOR was 13.1 (3.1; 55.0), LR+ was 2.9 (1.0; 8.1), LR− was 0.22 (0.1; 0.5). For patients with Tg-DT < 1 year (n = 247), the survival risk ratio was 2.09 (95% CI: 1.49; 2.94).
Conclusions
Tg-DT values are valuable in predicting response to treatment and disease recurrence in patients with DTC, as well as their overall survival. In addition, Tg-DT significantly increases the detection rate of 2-[18F]-FDG PET/CT.
Introduction
In many cases, differentiated thyroid carcinoma (DTC) has an indolent course and a generally favorable prognosis. However, recurrences may occur in up to 20% of DTC patients, with 10% of them having a fatal outcome (1). Serum thyroglobulin (Tg) is the pivotal DTC biomarker during the follow-up of these patients: an undetectable Tg level (after excluding interfering anti-Tg autoantibodies) is associated with excellent treatment response and favorable prognosis. In contrast, detectable Tg levels may signal persistent or recurrent disease. Moreover, absolute Tg concentrations are correlated with tumor load and are widely employed to assess the extension of the disease and evaluate the response to treatments (2). Nevertheless, this single tumor marker measurement may not be exhaustive in the comprehension of disease status and treatment response because it is not intrinsically inclusive of previous measurements and the overall trend (3). Therefore, evaluating dynamic changes in Tg concentration overtime is necessary to predict recurrence rates and overall survival. Tg doubling time (Tg-DT) has been demonstrated as a valuable biomarker to predict loco-regional recurrences, distant metastases, and survival independently from classical prognostic factors (e.g. TNM stage, age, and gender) (4). Recently, the Tg-DT was also proven useful to predict results of 2-[18F]fluoro-2-deoxy-d-glucose (2-[18F]FDG) PET/CT in patients with detectable Tg levels who had a negative radioiodine whole-body scintigraphy (WBS) (5, 6). Despite relevant literature, however, recent management guidelines contain little specific advice on the use and interpretation criteria of Tg-DT, and consequently, Tg-DT is sparsely adopted in clinical practice. Therefore, the present study was prompted to provide a systematic review and meta-analysis of updated literature to obtain more robust evidence on Tg-DT performance in DTC assessment. Specifically, we aimed to address three clinical questions:
-
Are Tg-DT values indicative of response to treatments in patients with DTC (i.e. ‘treatment monitoring’)?
-
Is Tg-DT predictive of (2-[18F]FDG) PET/CT results in patients with DTC?
-
Are Tg-DT values predictive of DTC prognosis (i.e. ‘prediction’)?
Materials and methods
Protocols and registration
The systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (7). The methodology was registered in the International prospective register of systematic reviews database under the protocol number CRD42021257947.
Eligibility criteria
All original peer-reviewed research publications were considered. Inclusion criteria for eligible studies were: (i) at least two consecutive Tg measurements under the thyroid hormone replacement therapy to calculate Tg kinetics; (ii) no interfering anti-Tg antibodies; (iii) prospective or retrospective studies.
Information sources and search strategy
A systematic search strategy was carried out on PubMed, Embase, Web of Science, and Scopus from May to July 2021 without time and language restrictions. The literature search strategy was based on the following keywords: (thyroglobulin) AND (doubling time OR doubling-time OR DT). Additionally, hand searches were performed to identify possible articles other than those found in the electronic databases. Finally, a further hand search of the citation lists of the included studies was performed. Two reviewers (L G and M G) performed the first (title/abstract screening) and second (full-text assessment) steps of the search process. Any disagreement was discussed and then solved by consensus.
Study selection
After removing duplicates and excluding not eligible articles, the potentially relevant articles were screened by reading titles and abstracts. Two reviewers selected the eligible studies (L G and M G) independently. Then, full texts of the eligible articles, that is those that met the inclusion and exclusion criteria, were retrieved. The final eligibility of each study was assessed, and the reasons for exclusion were recorded. Finally, two authors (L G and L C) executed the definitive article selection. In case of disagreement, it was resolved by discussion.
Data extraction
Data extraction was organized in tables containing the following information:
-
Study characteristics: first author, year, country.
-
Study’s sample size and patients’ characteristics (sex, mean age, % of males).
-
Number of patients with papillary thyroid cancer and number of patients with follicular thyroid cancer.
-
Poorly differentiated or Hürthle or aggressive variants.
-
Sample size included in Tg-DT calculation.
-
Follow-up in years.
-
Number of consecutive Tg level measurements used to determine Tg-DT.
-
Rates of disease progression or recurrence of DTC.
No numerical information was extracted from the figures reported in the study publications.
Quality assessment
Two authors independently assessed the risk of bias of included studies using the NIH quality assessment tool for observational cohorts (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools). The tool comprises 14 criteria; the overall assessment is rated good, fair, or poor. Possible disagreements were resolved by discussion and consensus among all authors.
Statistical analysis
The hierarchical summary receiver-operating characteristics (HSROC) and bivariate methods were performed to determine the predictivity of (2-[18F]FDG) PET/CT results in patients with DTC. For cells containing zero, the continuity correction of 0.5 was used (8). Positive likelihood ratios greater than 2.0 or negative likelihood ratios lower than 0.5 with 95% CIs not including 1.0 were considered statistically significant (9). The risk ratio for survival was summarized through the DerSimonian–Laird random-effects model due to the nature of the studies. We had hypothesized that the treatment effect was influenced not only by the residual effect but also by unexpected factors as unmeasured comorbidity, age, or tumor stage. Heterogeneity was assessed using Cochrane Q-test and the I² statistic, where a P -value <0.05 was taken to indicate statistically significant heterogeneity. According to the Cochrane Handbook for Systematic Reviews of Interventions, the ranges of interpretation for I² are as follows: 0–40% may be unimportant, 30–60% may represent moderate heterogeneity, 50–90% may represent substantial heterogeneity, and 75–100% may have considerable heterogeneity. Heterogeneity was also investigated through the L’Abbè plot: studies that deviated from the effect-size line considerably were reported as heterogeneity. Subgroup analyses were performed for studies mainly composed of patients with papillary thyroid cancer, studies carried out on more than 50 and 100 patients, respectively, and studies with at least 4 consecutive Tg measurements. Publication bias was not assessed because fewer than ten studies were included in the meta-analysis (10). A sensitivity analysis was performed to examine whether overall findings were robust to the chosen analysis method. Finally, the power of meta-analysis was calculated using the metapow command. Meta-analysis was carried out using STATA17 (StataCorp.).
Results
Study selection
The literature search identified 1830 studies. After removing duplicate records, 1685 studies were screened. Eleven studies between 2011 and 2021 met the inclusion and exclusion criteria (Fig. 1). Sixteen reports were excluded, mainly because it was irrelevant to the main topic.
Risk of bias
Five studies were good as assessed by the NIH tool (2, 11, 12, 13, 14). Sample size justification or power description was not reported in all included studies. In addition, the percentage of patients lost during the follow-up was not reported in several works (6, 11, 12, 13, 14, 15, 16). Quality assessment of the included studies has been reported in Supplementary Table 1 (see section on supplementary materials given at the end of this article).
Study characteristics
A total of 1421 patients were included (Table 1). Patients’ mean age ranged between about 40 and 77 years. Samples of seven studies were prevalently comprised of patients with papillary thyroid cancer for a total of 910 patients (4, 6, 12, 14, 15, 16, 17), while the remaining four studies were prevalently comprised of patients with follicular thyroid carcinoma for a total of 343 patients (5, 11, 13, 18). Six studies had a sample size lower than 100 patients (5, 13, 15, 16, 17, 18), while five studies had a larger sample size that ranged between 102 (6) and 426 (4) patients. The percentage of males/females ranged between 18.1 (4) and 59.6%(15). Tg-DT calculation was reported for 918 patients. Six studies used at least four TG level measurements to determine Tg-DT (12, 14, 15, 16). Two studies used at least three Tg level measurements (5, 13), while the remaining three studies used respectively two (6, 17) and five (18) Tg level measurements. Three studies (13, 14, 18) were carried out in Germany, three in Japan (4, 12, 16), one in Switzerland (6), France (17), Turkey (5), USA (15), and Italy (11), respectively. The median follow-up was 6.1 years ranging between 157 days (16) and 11.1 years (15).
Characteristics of the included studies (n = 11).
| Author | Year | Country | Patients | Mean age, year | % Males (male/female) | PTC | FTC | DTC type prevalence | Poorly differentiated or Hurthle or aggressive variant | TSH | Patients included for Tg-DT | Follow-up, year | Number of Tg measuraments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Miyauchi | 2011 | Japan | 426 | 51.5 | 18.1 (77/349) | 426 | 0 | PTC | 0 | Suppressed to < 0.1 mIU/L | 137 | 7.3 | ≥4 |
| Giovanella | 2013 | Switzerland | 102 | 48.2 | 24.5 (25/99) | 87 | 37 | PTC | 0 | Suppressed (range, <0.01–02 mIU/L) | 102 | 3.8 | 2 |
| Kelders | 2014 | Germany | 65 | 58 | 40 (26/39) | 14 | 29 | FTC | 2 | NR | 9 | NR | 5 |
| Rössing | 2016 | Germany | 99 | 16-77 | 37.3 (37/62) | 33 | 66 | FTC | 0 | TSH < 0.3 mIU/L | 99 | 4.7 | ≥3 |
| Wassermann | 2016 | France | 91 | <45 year: 14 (15%); ≥45 year: 77 (85%) | 38 (35/56) | 47 | 29 | PTC | 15 | TSH < 0.2 mIU/L | 31 | 8.7 | 2 |
| Verburg | 2017 | Germany | 174 | NR | 43 (75/99) | 102 | 72 | PTC | 0 | Suppressed | 174 | 8.9 | ≥4 |
| Manohar | 2018 | USA | 62 | 63.2 | 59.6 (37/25) | 44 | 18 | PTC | 0 | Suppressed | 50 | 11.1 | ≥4 |
| Iwasaki | 2019 | Japan | 147 | 70.3 | 41.6 (32/45) | 65 | 12 | PTC | 0 | TSH non-elevated without any further indication | 128 | 5.1 | ≥4 |
| Zhang | 2020 | Japan | 21 | 62.5 ± 14.1 | 47.6 (10/11) | 16 | 5 | PTC | 0 | TSH < 0.1 mIU/L | 21 | 157 days | ≥4 |
| Albano | 2021 | Italy | 139 | 56 | 54 (75/64) | 72 | 53 | FTC | 14 | Suppressed | 139 | 3.7 | ≥2 |
| Araz | 2021 | Turkey | 95 | 52.6 | 54 (15/13) | 4 | 22 | FTC | 2 | TSH < 0.1 mIU/L | 28 | 7.1 | 3 |
FTC, follicular thyroid carcinoma; NR, not reported; PTC, papillary thyroid carcinoma;Tg, thyroglobulin.
Is Tg-DT indicative of response to treatment in patients with DTC?
Five studies investigated the association between Tg-DT and DTC recurrence or disease progression (4, 12, 14, 16, 18) (Supplementary Table 2).
A positive association between Tg-DT < 1 year and recurrence or disease progression was observed in four studies (4, 14, 16, 18). Miyauchi et al. (4) reported higher rates of loco-regional recurrence in patients with Tg-DT < 1 year (43.8% at 5 years and 78.6% at 10 years) than in patients with Tg-DT ranging between 1 and 3 years (23.5% at 5 years, 72.6% at 10 years) and in patients with Tg-DT ≥ 3 years (23.6% at 5 years and 42.5% at 10 years) (4). Kelders et al. showed DTC progression in eight out of nine patients with Tg-DT < 1 year (18). Verburg et al., in a sample of 174 patients, observed recurrence in eight patients with Tg-DT < 1 year and no recurrence in patients with Tg-DT ≥ 1 year (14). Finally, Zhang et al. reported Tg-DT < 1 year in all patients with disease progression (16). Only one study reported no association between Tg-DT values and disease progression (12).
Is Tg-DT predictive of 2-[18F]FDG PET/CT results in patients with DTC?
Four studies were used to determine HSROC (5, 6, 11, 18). The area under the curve (AUC) was 0.86 (95% CI: 0.83; 0.89) (Fig. 2). The summary estimates of sensitivity and specificity were 0.84 (95% CI: 0.64; 0.94) and 0.71 (95% CI: 0.35; 0.92), respectively. The pooled estimates of L+, L−, and DOR were 2.9 (95% CI: 1.0; 8.1), 0.22 (95% CI: 0.1; 0.5), and 13.1 (95% CI: 3.1; 55.0), respectively.
Hierarchical summary receiver-operating characteristics (HSROC) plot for all included studies (n = 4). Area under the curve (AUC) = 0.86 (95% CI: 0.83–0.89); Sensitivity: 0.84 (0.64;0.94); Specificity: 0.71 (0.35; 0.92); DOR: 13.1 (3.1; 55.0); LR+: 2.9 (1.0; 8.1); LR−: 0.22 (0.1; 0.5).
Citation: Endocrine Connections 11, 4; 10.1530/EC-21-0648
Is Tg-DT predictive of survival outcomes in patients with DTC?
Seven studies were included in the principal comparative analysis about the survival risk ratio between patients with Tg-DT < 1 year and those with Tg-DT ≥ 1 year (4, 11, 12, 13, 14, 17).
For patients with Tg-DT < 1 year (n = 247), the risk ratio was 2.09 (95% CI: 1.49; 2.94) (test of 𝜗: z = 4.25, P < 0.001; test of homogeneity: Q = 𝜒2 (6) = 8.06, P = 0.23; I2 = 25.6%) (Fig. 3). L’Abbè Plot (Supplementary Fig. 1) showed that Miyauchi et al. (4) and Rössing et al. (13) were outliers. After outliers exclusion, the risk ratio for patients (n = 159) with Tg-DT < 1 year was 1.93 (95% CI: 1.47; 2.54) (test of 𝜗: z = 4.70, P < 0.001; test of homogeneity: Q = 𝜒2 (6) = 4.03, P = 0.40; I2 = 0.83%) (Fig. 4). The risk ratio increased in patients with papillary thyroid cancer and Tg-DT < 1 year (n = 127) (2.38 (95% CI: 1.71; 3.30; test of 𝜗: z = 5.16, P < 0.001; test of homogeneity: Q = 𝜒2 (4) = 2.49, P = 0.65; I2 = 0.00%) (Fig. 5). Risk ratio of patients with Tg-DT < 1 year showed no significantly changes after subgroup analysis related to sample size (Supplementary Figs 2 and 3). The risk ratio for patients with Tg-DT < 1 year determined with at least four Tg measurements (n = 122) was 2.35 (95% CI: 1.66; 3.33) (test of 𝜗: z = 4.82, P < 0.001; test of homogeneity: Q = 𝜒2 (3) = 2.45, P = 0.48; I2 = 0.00%) (Supplementary Fig. 4). The sensitivity analysis showed no relevant difference in the case of different meta-analysis approaches (random vs fixed) or change in effect-size measurements (RR vs OR) (Supplementary Table 3). Meta-analysis power was 82.9 (95% CI: 80.4; 85.2) (number of patients in each group: 54; level of significant = 0.05; number of simulations the power calculation is based on = 1000) (Supplementary Fig. 5).
Forest plot for all studies comparing survival for Tg-DT < 1 year vs Tg-DT ≥ 1 year (n = 7). Risk ratio = 2.09 (95% CI 1.49; 2.94). Number of survived and non-survived patients according to the Tg-DT values. Random-effects DerSimonian–Laird model.
Citation: Endocrine Connections 11, 4; 10.1530/EC-21-0648
Forest plot for studies comparing survival for Tg-DT < 1 year vs Tg-DT ≥ 1 year without outliers (n = 5). Risk ratio = 1.93 (95% CI 1.47; 2.54). Number of survived and non-survived patients according to the Tg-DT values. Random-effects DerSimonian–Laird model.
Citation: Endocrine Connections 11, 4; 10.1530/EC-21-0648
Subgroup analysis – forest plot for studies comparing survival for Tg-DT < 1 year vs Tg-DT ≥ 1 year composed mainly of patients with papillary thyroid carcinoma (n = 5). Risk ratio = 2.38 (95% CI 1.71; 3.39). Number of survived and non-survived patients according to the Tg-DT values. Random-effects DerSimonian–Laird model.
Citation: Endocrine Connections 11, 4; 10.1530/EC-21-0648
Discussion
Tumor marker DT has been a predictive marker for outcomes in patients with various types of cancer, such as prostate cancer (DT of prostate-specific antigen) (19, 20, 21, 22, 23) or medullary thyroid cancer (DT of calcitonin and carcinoembryonic antigen) (24). The first analysis dealing with calcitonin DT, published in the early 80s (25), showed that calcitonin DT highly correlated with life expectancy and tumor recurrence.
As the main result of our study, a Tg-DT < 1 year robustly predicted the response to treatment (’treatment monitoring’) and the patients’ outcome over time (’prediction’). In addition, Tg-DT values also emerged as reliable predictors of (2-[18F]FDG) PET/CT results. In particular, patients with Tg-DT < 1 year carry a higher risk of having an incomplete response to treatment and reduced survival than patients with longer Tg-DT. Among patients with negative radioiodine WBS, those with shorter Tg-DT values are more likely to have positive (2-[18F]FDG) PET/CT results that, in turn, confers a higher risk of reduced survival. The idea of a strict relationship between Tg kinetics and (2-[18F]FDG) PET/CT results is coherent and likely dependent on the aggressive behavior and high growing tumor rate of (2-[18F]FDG)-avid DTC, usually associated with worse prognosis. Several potential sources of between-study heterogeneity and uncertainty should be considered in this study. First, patients’ inclusion criteria varied significantly among the included studies. Rössing et al. (13) only included patients with proven structural persistent or relapsing disease after radioiodine therapy; Miyauchi et al. (4) included a more heterogeneous series of DTC patients including patients without radioiodine therapy. In Rossing et al. (13), the mortality risk of patients with a Tg-DT <5 months was more than twice as high as the mortality risk of patients with a Tg-DT of >14 months. Multivariate analysis, including the covariates of the prevalence of distant or locoregional metastases, Tg blood level, and degree of radioiodine accumulation, confirmed a doubling of mortality risk of patients with a Tg-DT <5 months compared to a Tg-DT of >14 months. However, it was not possible to confirm Tg-DT as an independent predictor for survival rate for all patients with progressive disease. However, when focusing on patients with a Tg level (geometric mean) >100 ng/mL representing a high tumor load, significant differences were found in survival rates when the Tg-DT was classified into the three groups < 3 months, 3–12 months, and >12 months (P < 0.05). This is not surprising as patients with lower Tg levels are likely those with reduced tumor burden and increased radioiodine avidity, increasing the weight of such covariates. However, in line with other included studies, a Tg-DT of 14 months or more remained a robust favorable prognostic predictor even in patients with high tumor load.
Secondly, follow-up periods ranged from 157 days to 11.1 years in different studies. A unique feature of survival data is that not all patients experience the event (i.e. recurrence, death) by the end of the observation period (i.e. censoring phenomenon). This is more likely when a short follow-up period is available. Consequently, fewer events are expected in studies with shorter follow-up than those with more extended observation periods (26). On the other hand, a reduced Tg-DT predicted an increased risk of major events in patients only followed for short periods. Accordingly, a significant impact of follow-up length on our results seems unlikely.
Thirdly, a different number of Tg measurements (from two to five) and mathematical methods were adopted to calculate Tg-DT values in included studies. The accuracy of the determined Tg-DT increases with the number of available Tg measurements. Rössing et al. (13) showed in their study that the mean estimated error of Tg-DT was inversely correlated with the number of Tg measurements, being 21% for three measurements and decreasing to 8% for seven or more measurements. But even if different timing and measurement points may have influenced Tg kinetic evaluation, a Tg-DT < 1 year was homogeneously related to an increased risk of major events and positive (2-[18F]FDG) PET/CT results. Moreover, no major differences between mathematical methods to determine kinetic parameters were reported (3).
Fourthly, different Tg and TgAb assays were employed, and inter-assays variability results should be considered in comparing studies. However, if the same assays are used in individual patients, the Tg-DT values remain comparable as opposed to the absolute Tg values (27, 28). Finally, it should be noted that an increase in Tg does not always reflect tumor progression: pitfalls are, for example, therapeutically induced re-differentiation effects that can occur both under therapy with retinoids (29, 30) and under specific protein kinase inhibitors (31). In spite of a tumor regress proven by morphological and functional imaging, a Tg increase can occur here (as an expression of increasing differentiation of the tumor cells), and the aforementioned prognostic statements for the Tg-DT do not apply.
Fifthly, the degree of TSH might affect Tg levels and, consequently, Tg-DT values. Interestingly, Angell and colleagues previously demonstrated that a significant influence on the Tg measurement is not detectable for TSH values below 0.5 mUI/L (32). As shown in Table 1, TSH below 0.3, 0.2, and 0.1 mUI/L were reported in 781, 682, and 360 patients, respectively. Indeed, TSH levels were not reported by Kelders and colleagues (9 patients) (18), while Iwasaki and colleagues reported non-elevated TSH levels with any additional information (128 patients), respectively (12). Both studies included patients with advanced metastatic disease for whom clinical guidelines recommend TSH suppression. Accordingly, it is reasonable to expect suppressed TSH values in most patients. All in all, a significant confounding effect of TSH levels is unlikely in our analyzed patients’ populations.
Conclusions
Our results indicate that Tg-DT values are valuable in predicting response to treatment and disease recurrence in patients with DTC, as well as their overall survival. In addition, Tg-DT significantly increases the detection rate of (2-[18F]FDG) PET/CT. According to our findings, Tg-DT values <1 year should alert the thyroid team and prompt more aggressive diagnostic and therapeutic approaches. However, standardization of Tg-DT evaluation (i.e. the timing of Tg measurements, kinetic model, and calculation method) and large clinical multicentre studies are required to define better the role of Tg-DT in this setting.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/EC-21-0648.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
The present study did not receive any specific grant from any funding agency in the public, commercial, or non-for-profit sector.
References
- 1↑
Avram AM, Zukotynski K, Nadel HR, Giovanella LM. Management of differentiated thyroid cancer: the standard of care. Journal of Nuclear Medicine 2022 63 189–195. (https://doi.org/10.2967/jnumed.121.262402)
- 2↑
Giovanella L Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. Current Opinion in Oncology 2020 32 7–12. (https://doi.org/10.1097/CCO.0000000000000588)
- 3↑
Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clinical Chemistry 1999 45 1695–1707. (https://doi.org/10.1093/clinchem/45.10.1695)
- 4↑
Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M & Inoue H et al.Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011 21 707–716. (https://doi.org/10.1089/thy.2010.0355)
- 5↑
Araz M, Soydal Ç, Ozkan E, Akkus P, Nak D, Kucuk NÖ, Kir KM. Role of thyroglobulin doubling time in differentiated thyroid cancer and its relationship with demographic-histopathologic risk factors and (18)F-fluorodeoxyglucose positron emission tomography/computed tomography parameters. Cancer Biotherapy and Radiopharmaceuticals 2021 36 425–432. (https://doi.org/10.1089/cbr.2019.3203)
- 6↑
Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, Foppiani L, Ceriani L. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 874–880. (https://doi.org/10.1007/s00259-013-2370-6)
- 7↑
Moher D, Liberati A, Tetzlaff J, Altman DG & PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009 6 e1000097. (https://doi.org/10.1371/journal.pmed.1000097)
- 8↑
Kim KW, Lee J, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part I. General guidance and tips. Korean Journal of Radiology 2015 16 1175–1187. (https://doi.org/10.3348/kjr.2015.16.6.1175)
- 9↑
McGee S Simplifying likelihood ratios. Journal of General Internal Medicine 2002 17 646–649. (https://doi.org/10.1046/j.1525-1497.2002.10750.x)
- 10↑
Page MJ, Higgins JPT & Sterne JAC Tests for funnel plot asymmetry #section-13-3-5-4. In Assessing risk of bias due to missing results in a synthesis. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2016. (available at: https://training.cochrane.org/handbook/current/chapter-13#section-13-3-5-4)
- 11↑
Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Bertagna F, Giubbini R. The role of Tg kinetics in predicting 2-[(18)F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. Endocrine 2021 74 332–339. (https://doi.org/10.1007/s12020-021-02755-5)
- 12↑
Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Hatori S, Toda S, Masudo K. Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncology Letters 2019 17 5292–5300. (https://doi.org/10.3892/ol.2019.10180)
- 13↑
Rossing RM, Jentzen W, Nagarajah J, Bockisch A, Gorges R. Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid 2016 26 1712–1718. (https://doi.org/10.1089/thy.2016.0031)
- 14↑
Verburg FAM, Mäder U, Grelle I, Giovanella L, Reiners C, Hänscheid H. Only a rapid complete biochemical remission after 131I-therapy is associated with an unimpaired life expectancy in differentiated thyroid cancer. Hormone and Metabolic Research 2017 49 860–868. (https://doi.org/10.1055/s-0043-119462)
- 15↑
Manohar PM, Beesley LJ, Bellile EL, Worden FP, Avram AM. Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clinical Nuclear Medicine 2018 43 641–647. (https://doi.org/10.1097/RLU.0000000000002193)
- 16↑
Zhang X, Higuchi T, Tomonaga H, Lamid-Ochir O, Bhattarai A, Nguyen-Thu H, Taketomi-Takahashi A, Hirasawa H, Tsushima Y. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. Nuclear Medicine Communications 2020 41 350–355. (https://doi.org/10.1097/MNM.0000000000001154)
- 17↑
Wassermann J, Bernier MO, Spano JP, Lepoutre-Lussey C, Buffet C, Simon JM, Menegaux F, Tissier F, Leban M, Leenhardt L. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist 2016 21 50–58. (https://doi.org/10.1634/theoncologist.2015-0107)
- 18↑
Kelders A, Kennes LN, Krohn T, Behrendt FF, Mottaghy FM, Verburg FA. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions. Nuclear Medicine Communications 2014 35 176–181. (https://doi.org/10.1097/MNM.0000000000000025)
- 19↑
Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW & Lee A et al.Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. Journal of Urology 2008 179 2181–2185; discussion 5–6.
- 20↑
Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. Journal of Urology 2006 176 1927–1937. (https://doi.org/10.1016/j.juro.2006.07.002)
- 21↑
Ponholzer A, Popper N, Breitenecker F, Schmid HP, Albrecht W, Loidl W, Madersbacher S, Schramek P, Semjonow A, Rauchenwald M. Proposal for a standardized PSA doubling-time calculation. Anticancer Research 2010 30 1633–1636.
- 22↑
Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006 106 1047–1053. (https://doi.org/10.1002/cncr.21696)
- 23↑
Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology 2014 83 592–596. (https://doi.org/10.1016/j.urology.2013.09.075)
- 24↑
Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA, Smit JW. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology 2010 72 534–542. (https://doi.org/10.1111/j.1365-2265.2009.03666.x)
- 25↑
Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Annals of Surgery 1984 199 461–466. (https://doi.org/10.1097/00000658-198404000-00014)
- 26↑
Schober P, Vetter TR. Survival analysis and interpretation of time-to-event data: the tortoise and the hare. Anesthesia and Analgesia 2018 127 792–798. (https://doi.org/10.1213/ANE.0000000000003653)
- 27↑
Cappelli G Mathematical model application to the kinetic study of tumor markers. International Journal of Biological Markers 1994 9 8–14. (https://doi.org/10.1177/172460089400900102)
- 28↑
Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Research 1996 16 2279–2284.
- 29↑
Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A, Olczyk T, Piela A, Paliczka-Cieslik E, Jarzab B. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Research 2009 2 8. (https://doi.org/10.1186/1756-6614-2-8)
- 30↑
Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World Journal of Surgery 1998 22 569–574. (https://doi.org/10.1007/s002689900436)
- 31↑
Leboulleux S, Dupuy C, Lacroix L, Attard M, Grimaldi S, Corre R, Ricard M, Nasr S, Berdelou A & Hadoux J et al.Redifferentiation of a BRAF(K601E)-mutated poorly differentiated thyroid cancer patient with Dabrafenib and trametinib treatment. Thyroid 2019 29 735–742. (https://doi.org/10.1089/thy.2018.0457)
- 32↑
Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 2014 24 1127–1133. (https://doi.org/10.1089/thy.2013.0691)
